Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $584,052 - $653,060
-10,089 Reduced 71.0%
4,121 $239,000
Q2 2023

Aug 08, 2023

SELL
$63.71 - $70.74 $13,888 - $15,421
-218 Reduced 1.51%
14,210 $908,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $347,934 - $394,636
-5,295 Reduced 26.85%
14,428 $1 Million
Q4 2022

Feb 16, 2023

SELL
$68.48 - $81.09 $79,573 - $94,226
-1,162 Reduced 5.56%
19,723 $1.42 Million
Q3 2022

Oct 18, 2022

SELL
$0.13 - $76.84 $11 - $6,761
-88 Reduced 0.42%
20,885 $1.49 Million
Q2 2022

Jul 20, 2022

SELL
$72.62 - $79.98 $408,850 - $450,287
-5,630 Reduced 21.16%
20,973 $1.62 Million
Q1 2022

May 02, 2022

SELL
$61.48 - $73.72 $73,407 - $88,021
-1,194 Reduced 4.3%
26,603 $1.94 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $148,715 - $173,367
-2,773 Reduced 9.07%
27,797 $1.73 Million
Q3 2021

Oct 22, 2021

SELL
$59.17 - $69.31 $62,069 - $72,706
-1,049 Reduced 3.32%
30,570 $1.81 Million
Q2 2021

Jul 29, 2021

BUY
$61.91 - $67.42 $119,486 - $130,120
1,930 Added 6.5%
31,619 $2.11 Million
Q1 2021

Aug 11, 2021

SELL
$59.34 - $66.74 $82.4 Million - $92.7 Million
-1,388,395 Reduced 97.91%
29,689 $1.87 Million
Q1 2021

May 05, 2021

BUY
$59.34 - $66.74 $83.9 Million - $94.3 Million
1,413,484 Added 30727.91%
1,418,084 $89.5 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $32,281 - $42,108
-656 Reduced 12.48%
4,600 $295,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $32,281 - $42,108
656 Added 14.26%
5,256 $337,000
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $27,843 - $33,012
-651 Reduced 12.4%
4,600 $233,000
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $27,843 - $33,012
651 Added 14.15%
5,251 $266,000
Q2 2017

Aug 21, 2017

BUY
N/A
4,600
4,600 $256,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Gsb Wealth Management, LLC Portfolio

Follow Gsb Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsb Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gsb Wealth Management, LLC with notifications on news.